Chairs: Margaret Zhou (USA) – Emanuele Asti (Italy) – Kee Wook Jung (Korea)

1. Do we know the precursor of Barrett’s esophagus? – Ines Gockel (Germany)
2. Is intestinal metaplasia of the EGJ truly Barrett’s esophagus – and does it matter? – Maha M. Guindi (USA)
3. What is the role of the microbiome in Barrett’s esophagus & can it be a target for screening or therapy? – Margaret Zhou (USA)
4. Who should be screened for Barrett’s esophagus? – Kenneth Vega (USA)
5. What is the current role for non-invasive Barrett’s screening modalities? – Prasad Iyer (USA)
6. How should endoscopy be performed for patients with suspected or known Barrett’s esophagus? – Marcia (Mimi) Canto (USA)
7. How should we assess risk of progression after diagnosis? – Kerry Dunbar (USA)
8. What is the role of endoscopic ultrasound in Barrett’s esophagus & should it be mandatory? – Eun Ji Shin (USA)
9. How to choose between radiofrequency ablation & cryotherapy for ablation? – Shai Friedland (USA)
10. Should nodular Barrett’s be removed with EMR or ESD? – Daryl Ramai (USA)
11. Should all patients with Barrett’s esophagus be offered anti-reflux surgery? – Emanuele Asti (Italy)
12. Are there patients for whom we can recommend against future surveillance? – Massimiliano Di Pietro (UK)

Panel Chat/Q&A